Spotlight on peginterferon-α-2a (40kd) plus ribavirin in the management of chronic hepatitis c mono-infection

BioDrugs

Volumn 23, Issue 1, 2009, Pages 63-68

  Keam, Susan J ^a   Cvetković, Risto S ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; GENOTYPE; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; LIVER DISEASE; LIVER FIBROSIS; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 64349121739     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200923010-00007     Document Type: Article

References (77)

1. Keam SJ, Cvetkovic RS. Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection. Drugs 2008; 68 (9): 1273-317
2. Roche Laboratories Inc. Pegasys® (peginterferon alfa-2a): complete product infor- mation [online]. Available from URL: http://www.rocheusa.com/ products/pegasys/pi.pdf [Accessed 2008 Mar 13]
3. Keating GM, Curran MP. Peginterferon-α-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2003; 63 (7): 701-30
4. Roche Products Limited. Copegus® 200mg film-coated tablet: UK/Ireland summary of product characteristics [online]. Available from URL: http://rocheuk.com [Accessed 2006 Feb 15]
5. Riva A, Della Bella S, Benetti A, et al. PEG-IFN-alpha plus ribavirin combined therapy restores circulating IFN-alpha-producing dendritic cells in patients with chronic hepatitis C virus infection [abstract no. 598]. J Hepatol 2005; 42 Suppl. 2: 218
6. Kamal SM, He Q, Ismail A, et al. Impaired allostimulatory function of den- dritic cells in acute hepatitis C favors chronicity [abstract no. 409]. Gastroenterology 2004; 126 (Suppl. 2): A681
7. European Medicines Agency. Pegasys®: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int [Accessed 2008 Mar 13]
8. Glue P, Schenker S, Gupta S, et al. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Br J Clin Pharmacol 2000 May; 49: 417-21
9. Roche Laboratories Inc. Copegus® (ribavirin, USP) tablets: complete product information [online]. Available from URL: http://www.roche.us [Accessed 2008 Mar 13]
10. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-α-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 Mar 2; 140 (5): 346-55
11. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 Sep 26; 347 (13): 975-82
12. Zarski J-P, Smith C, Hadziyannis S, et al. Are there differences in baseline characteristics or treatment outcomes with peginterferon α-2a (40 kDa) and ribavirin in patients infected with HCV genotype 1A versus 1B [abstract no. 624]. J Hepatol 2005 Apr 1; 42 Suppl. 2: 228
13. Weiland O, Fried M, Hadziyannis S, et al. Peginterferon α-2a (40 kDa) (Pegasys®) plus ribavirin in treatment-naive patients with chronic hepatitis C and genotype 2 or 3 infection: individual estimated probability of sustained virological response [abstract no. 619]. J Hepatol 2005 Apr; 42 Suppl. 2: 226. Plus poster presented at the 40th Annual Meeting of the European Asociation for the Study of the Liver; 2005 Apr 13-17; Paris
14. Rodriguez-Torres M, Sulkowski M, Chung RT, et al. Association of pretreatment and on-treatment factors with rapid virological response in HCV genotype 1 infected patients treated with PEGIFnot-2a/RBV [abstract no. 1305]. Hepatology 2007; 46 (4 Suppl. 1): 817A
15. Di Bisceglie AM, Hassanein TI, Jeffers LJ, et al. Association of pretreatment and on-treatment factors with null response in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin [abstract]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
16. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007 Jul 12; 357 (2): 124-34
17. Weiland O, Fried MW, Hadziyannis SJ, et al. Combination therapy with peginterferon alfa-2a (40 kD) (Pegasys®) plus ribavirin (Copegus®) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: individual estimated probability of sustained virological response (SVR) [abstract no. 522]. J Hepatol 2004 Apr; 40 (Suppl. 1): 154
18. Backus LI, Boothroyd DB, Phillips BR, et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007 Jul; 46 (1): 37-47
19. Foster GR, Fried MW, Hadziyannis SJ, et al. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kD) and ribavirin. Scand J Gastroenterol 2007 Feb; 42 (2): 247-55
20. Snoeck E, Hadziyannis SJ, Puoti C, et al. Predicting efficacy and safety out-comes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon ot-2a (40 kD) plus ribavirin. Liver Int 2008 Jan; 28 (1): 61-71
21. Crawford DHG, Roberts S, WeltmanM, etal. Baseline factors associated with rapid and early virological responses in HCV genotype 1 patients treated with induction dosing of pegylated interferon: the CHARIOT study. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
22. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kD)/ribavirin therapy. Hepatology 2006 Apr 20; 43 (5): 954-60
23. Marcellin P, Hadziyannis SJ, Berg T, et al. Virological response at 4 and 12 weeks predict high rates of sustained virological response in genotype 1 patients treated with peginterferon α-2a (40 kD) plus ribavirin [abstract no. 613]. J Hepatol 2007; 46 Suppl. 1: S231
24. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kD)/ribavirin. J Hepatol 2005 Sep; 43 (3): 425-33
25. Reddy K, Rakela J, Lopez-Talavera J, et al. Correlations between rapid virologic response, early virologic response and sustained virologic response in HCV genotype 1 patients treated with pegylated interferon alfa-2a and ribavirin [abstractno. S1540]. Gastroenterology 2005 May 15; 128 (4 Suppl. 2): 715
26. Marcellin P, Jensen DM, Hadziyannis SJ, et al. Differentiation of early virologic response (EVR) into RVR, complete EVR (CEVR) and partial EVR (PEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40 kD) (Pegasys®) and ribavirin (Copegus®) [abstract no. 1308]. Hepatology 2007 Oct; 46 (4 Suppl. 1): 818A
27. Shiffman ML, Chung RT, Hamzeh FM. Time to HCV RNA undetectability supercedes baseline factors in predicting SVR in patients with HCV genotype 1 [abstract]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
28. Fried MW, Hadziyannis SJ, Shiffman M, et al. Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection [abstract]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
29. Swain MG, Lai M, Shiffman ML, et al. Sustained virologic response resulting from treatment with peginterferon alfa-2a (40 kD) (Pegasys®) alone or in combination with ribavirin (Copegus®) is durable and constitutes a cure: an ongoing 5-year follow-up [abstract no. 444]. Digestive Disease Week 2007; 2007 May 19-24; Washington, DC
30. Ferenci P, Laferl H, Scherzer T-M, et al. Response-guided therapy in a prospective trial of peginterferon alfa-2a (40KD)/ribavirin treatment in patients with genotypes 1 or 4 [abstract no. 1301]. Hepatology 2007 Oct; 46 (4 Suppl. 1): 814-85A. Plus poster presented at the 58th Annual Meeting of the American Association for the Study of Liver Disease; 2007 Nov 2-6; Boston (MA)
31. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006 Apr; 130 (4): 1086-97
32. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006 Aug; 131 (2): 451-60
33. Ferenci P, Laferl, Scherzer T-M, et al. Customizing treatment with peginterferon alfa-2a (40 kD) (Pegasys®) plus ribavirin (Copegus®) in patients with HCV genotype 1 or 4 infection: interim results of a prospective randomized trial [abstract no. 390]. Hepatology 2006; 44 (4 Suppl. 1): 336A
34. Roberts S, Weltman M, Crawford D, et al. Rapid and early virological response rates are increased with 12 week 360μg/wk peginterferon alfa-2A (40 kD) and standard ribavirin in HCV genotype 1 treatment naive patients: efficacy and safety analysis of the induction phase of the CHARIOT study [abstract no. 54]. Hepatology 2007 Oct; 46 (4 Suppl. 1): 257-28A
35. Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008 Jun; 47 (6): 1837-45
36. Mecenate F, Barbaro G, Pellicelli A, et al. Comparison of peginterferon alfa-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2 or 3: the CLEO Trial [abstract no. 1327]. Hepatology 2007 Oct; 46 (4 Suppl. 1): 828A
37. Von Wagner M, Huber M, Berg T, et al. Peginterferon-oc-2a (40 kD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005 Aug; 129 (2): 522-7
38. Ferenci P, Brunner H, Laferl H, et al. A randomized prospective trial of ribavirin 400mg/day versus 800mg/day in combination with peginterferon alfa-2a in HCV genotypes 2 and 3. Hepatology 2008 Jun; 47 (6): 1816-23
39. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007 Jan; 5 (1): 124-9
40. Lee JS, Hu S, Lopez-Talavera JC. Ribavirin (RBV) dose reduction in patients with HCV genotype 1 infection receiving combination treatment with peginterferon alfa-2a (40 kD) (Pegasys®) plus RBV (Copegus®) [abstract no. 394]. Hepatology 2004 Oct; 40 (4 Suppl. 1): 335A. Plus poster presented at the 55th Annual Meeting of the American Association for the Study of Liver Disease; 2004 Oct 29-Nov 2; Boston (MA)
41. Andriulli A, CursaroC, Cozzolongo R, etal. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to peginterferon alfa-2a and ribavirin [abstract no. 234]. Hepatology 2007 Oct; 46 (4 Suppl. 1): 342A
42. Jensen DM, Freilich B, Andreone P, et al. Pegylated interferon alfa-2a (40 kD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12kD)/RBV: final efficacy and safety outcomes of the REPEAT study [abstract no. LB4]. Hepatology 2007; 46 (4 Suppl. 1): 291A
43. Diago M, Hassanein T, Rodes J, et al. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-α 2a and ribavirin [letter]. Ann Intern Med 2004; 140 (1): 72-3
44. Diago M, Boadas J, Planas R, et al. Chronic hepatitis C genotype 4: efficacy and safety of the treatment with peginterferon alfa-2a plus ribavirin [abstract]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
45. Shobokshi O, Serebour FE, Skakni L, et al. Week 12 EVR predicts EOT in CHC genotype 4 patients treated with peginterferon alfa-2a (40 kD)/RBV [abstract no. 593]. J Hepatol 2003 Apr; 38 Suppl. 2: 172
46. Marcellin P, Roberts S, Alberti A, et al. Sustained virological and biochemical responses to peginterferon alfa-2a (40 kD) (Pegasys®) plus ribavirin (Copegus®) in patients with chronic hepatitic C (CHC) and compensated cirrhosis/bridging fibrosis [abstract no. 531]. Hepatology 2004; 40 Suppl. 1: 394A. Plus poster presented at the 55th Annual Meeting of the American Association for the Study of Liver Disease; 2004 Oct 20-Nov 2; Boston (MA)
47. Helbling B, Jochum W, Stamenic I, et al. HCV-related advanced fibrosis/ cirrhosis: randomized controlled trial of pegylated interferon oc-2a and ribavirin. J Viral Hepat 2006 Nov; 13 (11): 762-9
48. Everson GT, Hoefs JC, Seeff LB, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006 Dec; 44 (6): 1675-84
49. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004 Apr; 126(4): 1015-23
50. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peg- interferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007 Jan; 132 (1): 103-12
51. Lok AS, Seeff LB, Morgan TR, et al. Incidence rates and risk factors associated with hepatocellular carcinoma (HCC) in patients with advanced liver disease due to hepatitis C: results of the HALT-C trial [abstract]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
52. Shiffman ML, Morishima C, Lindsay KL, et al. Suppression of serum HCV RNA levels during maintenace peginterferon (PEGIFN) alfa-2a therapy and clinical outcomes in the HALT-C trial [abstract]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
53. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged antiviral therapy with peginterferon to prevent complications of advanced liver disease associated with hepatitis C: results of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial [abstract no. LB1]. Hepatology 2007; 46 (4 Suppl. 1): 290A
54. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006 Aug; 131 (2): 470-7
55. Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 kD) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004 Jun; 39 (6): 1702-8
56. Rodriguez-Torres M, Jeffers Lj, Sheikh MY, et al. Virologic responses to peginterferon alfa-2a/ribavirin in treatment-naïve Latino vs non-Latino Caucasians infected with HCV genotype 1: the Latino study [abstract]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
57. Kuboki M, Iino S, Okuno T, et al. Peginterferon α-2a (40 kD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. J Gastroenterol Hepatol 2007; 22 (5): 645-52
58. Yamada G, Iino S, Okuno T, et al. Virological response in patients with he- patitis C virus genotype 1b and a high viral load: impact of peginterferon-α-2a plus ribavirin dose reductions and host-related factors. Clin Drug Investig 2008; 28 (1): 9-16
59. Yu M-L, Dai C-Y, Huang J-F, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007 Apr; 56 (4): 553-9
60. Alberti A, Ascione A, Colombo M, et al. Antiviral treatment for hepatitis C virus infection in the real practice: a nationwide Italian experience (the PROBE study) [abstract no. O.064]. J Clin Virol 2006; 36 Suppl. 2: S20
61. Pinzello G, Stroffolini T, Vinci M, et al. HCV genotype 4 in subjects undergoing antiviral treatment in Italy [abstract]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
62. Craxi A, Piccinino F, Alberti A, et al. Predictors of SVR in naive HCV G1 patients in real life practice: the PROBE [abstract]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
63. Rizzetto M, Colombo M, Ascione A, et al. Effectiveness of hepatitis C virus treatment in real-life practice: a prospective observational multicenter study in Italy (PROBE) [abstract]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
64. Lee SS, Bain VG, PeltekianK, etal. Treating chronic hepatitisCwith pegylated interferon alfa-2a (40 kD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006 Feb; 23 (3): 397-408
65. Sherman M, Yoshida EM, Deschenes M, et al. Peginterferon alfa-2a (40 kD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006; 55 (11): 1631-8
66. Deschenes M, Yoshida E, Peltekian K, et al. Management of chronic hepatitis C in a diverse population with peginterferon α-2a (40 kDa) plus ribavirin: final results of the Canadian Pegasys Expanded Access Program (EAP) [abstract no. 615]. J Hepatol 2007; 46 Suppl. 1: S232-3
67. Bain VG, Lee SS, Peltekian K, et al. Clinical trial: exposure to ribavarin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin. The Canadian Pegasys Study Group. Aliment Pharmacol Ther 2008 Jul; 28 (1): 43-50
68. Zehnter E, Mauss S, John C, et al. Predictive factors in treatment of chronic hepatitis C patients with peginterferon alfa-2a (40 kD) and ribavirin [abstract no. T1813]. Gastroenterology 2006 Apr 1; 130 (4 Suppl. 2): 839.
69. Plus poster presented at Digestive Disease Week 2006; 2006 May 20-25; Los Angeles (CA)
70. Zehnter E, Huppe D, Mauss S, et al. Efficacy of peginterferon alfa-2a (40 kD) (Pegasys®) and ribavirin in patients with chronic hepatitis C in a real world setting - a contribution to health care research [abstract no. 1233]. Hepatol-ogy 2005 Oct; 42 (4 Suppl. 1): 683A. Plus poster presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases; 2005 Nov 11-15; San Francisco (CA)
71. Zehnter E, Mauss S, Hueppe D, et al. Efficacy and tolerability of peginterferon alfa-2a (40 kD) and ribavirin in genotype 4 patients with chronic hepatitis C (CHC) under real life conditions [abstract]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
72. Witthoft T, Moller B, Wiedmann KH, et al. Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: the German Open Safety Trial. J Viral Hepat 2007 Nov; 14 (11): 788-96
73. Witthoeft T, Hueppe D, John C, et al. Efficacy and safety of peginterferon alfa-2a or -2b plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Germany: the PRACTICE study [abstract]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
74. Mauss S, Hueppe D, John C, et al. Estimating the likelihood of sustained virological response in chronic hepatitis C (CHC) therapy [abstract]. 43rd Annual Meeting of the European Association for the Study of the Liver; 2008 Apr 23-27; Milan
75. Diago M, Sola R, Olveiera A, et al. Peginterferon alpha-2a (40 kD) (Pegasys®) plus ribavirin (Copegus®) for treating chronic hepatitis C genotype 1 in routine daily clinical practice: final results of the Heracles Project [abstract no. 567]. J Hepatol 2006; 44 Suppl. 2: S211
76. Bourliere M, Ouzan D, Rosenheim M, et al. Efficacy of peginterferon alfa-2a and ribavirin in 2101 patients with HCV infection in real-life clinical practice: results of the French HEPATYS study [abstract]. Hepatology 2007 Oct 1; 46 (4 Suppl. 1): 366A
77. Sanchez-Tapias JM, Crespo J, Diago M, et al. Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naive patients with chronic hepatitis C virus infection without early virological response at week 4. Methods Find Exp Clin Pharmacol 2002 Nov; 24 (9): 579-84